BioTuesdays

Category - Executive Moves

Merus Labs appoints two senior executives

Merus Labs International (NASDAQ:MSLI; TSX:MSL) has appointed two key additions to its executive leadership team, effective July 1.Dr. Michael Bumby was named CFO, succeeding Andrew Patient, who has decided to leave the...

Joint Corp. names Peter Holt as acting CEO

The employment of John Richards as CEO of the Joint Corp. (NASDAQ:JYNT) has been terminated by mutual agreement, effective June 30.  Mr. Richards also resigned as a director. Peter Holt, who was previously COO, was...

Marc Becker joins CRISPR Therapeutics as CFO

Closely-held CRISPR Therapeutics has appointed Marc Becker as CFO to further support the company’s efforts to develop game-changing drugs derived from its proprietary CRISPR-Cas9 gene-editing technology platform.Mr...

Rigel Pharma names Anne-Marie Duliege as CMO

Rigel Pharmaceuticals (NASDAQ:RIGL) has appointed Dr. Anne-Marie Duliege, as CMO, replacing Dr. Elliott Grossbard, who is retiring after 14 years with the company.Dr. Grossbard will remain with the company, advising on...

Shaunak Deepak joins H.C. Wainwright

Shaunak Deepak has joined H.C. Wainwright as a managing director and senior biotechnology analyst in the firm’s equity research group.Mr. Deepak previously was a VP and biotech analyst with Jefferies since 2009. He also...

Galectin Therapeutics

Galectin appoints Dr. Marc Rubin as chairman

Galectin Therapeutics (NASDAQ:GALT) has announced the election of Dr. Marc Rubin as chairman, succeeding James Czirr, who helped found the company in 2000. Mr. Czirr will continue as a director.Dr. Rubin is a leading...